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G R A P H I C A L A B S T R A C T
Brief burst-suppressing isoflurane anesthesia have been shown to produce antidepressant effects in patients, and in mice to bring phosphorylation effects on TrkB
receptor and GSK3β kinase similar to those seen with rapid-acting antidepressant ketamine. We investigated whether the emergence of burst-suppression pattern, a
neurophysiological correlate of deep anesthesia, is required for these molecular changes induced by isoflurane. Isoflurane dose-dependently regulates TrkB and
GSK3β phosphorylation and most prominent changes are observed when EEG burst suppression emerge, thus with a dosing associated with antidepressant effects.







A B S T R A C T
Objectives: Deep burst-suppressing isoflurane anesthesia regulates signaling pathways connected with anti-
depressant responses in the rodent brain: activation of TrkB neurotrophin receptor and inhibition of GSK3β
kinase (glycogen synthase kinase 3β). The main objective of this study was to investigate whether EEG (elec-
troencephalogram) burst suppression correlates with these intriguing molecular alterations induced by iso-
flurane.
Methods: Adult male mice pre-implanted with EEG recording electrodes were subjected to varying concentra-
tions of isoflurane (1.0–2.0% ad 20min) after which medial prefrontal cortex samples were collected for mo-
lecular analyses, and the data retrospectively correlated to EEG (+/- burst suppression).
Results: Isoflurane dose-dependently increased phosphorylation of TrkBY816, CREBS133 (cAMP response element
binding protein), GSK3βS9 and p70S6kT412/S424. The time spent in burst suppression mode varied considerably
between individual animals. Notably, a subset of animals subjected to 1.0–1.5% isoflurane showed no burst
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suppression. While p-GSK3βS9, p-CREBS133 and p-p70S6kT412/S424 levels were increased in the samples obtained
also from these animals, p-TrkBY816 levels remained unaltered.
Conclusions: Isoflurane dose-dependently regulates TrkB and GSK3β signaling and dosing associated with
therapeutic outcomes in depressed patients produces most prominent effects.
1. Introduction
General anesthetics (GA), such as halogenated hydrocarbon iso-
flurane, are widely used in medical and experimental operations re-
quiring surgical anesthesia. GAs strongly and rapidly alter brain´s
electrical activity and as the concentration of an anesthetic is increased
so-called burst suppression state is eventually reached [1,2]. Alter-
nating periods of low voltage EEG (electroencephalogram) activity and
high‐voltage electrical bursting activity are characteristic for this state.
The durations of suppressed periods are prolonged as anesthesia further
deepens, finally progressing into intermittent periods of isoelectric EEG
(i.e. electrocerebral silence). Notably, these neurophysiological signs of
deep anesthesia can be achieved with remarkably similar dosing of
volatile and gaseous anesthetics in mice and men.
The efficacy and onset of action of electroconvulsive therapy (ECT),
among the most potent antidepressant in the clinical domain, have been
associated with post-ictal (i.e. after seizure) emergence of burst sup-
pression EEG pattern [3,4]. This encouraged early investigations to test
the intriguing possibility that mere “electrocerebral silence” induced by
GAs produces antidepressant effects equal to those produced by the
ECT. While some of these clinical studies, especially those carried out
with isoflurane, appeared promising also conflicting results were re-
ported [5–7]. We recently translated this treatment into the preclinical
context and demonstrated that isoflurane anesthesia rapidly regulates
some of the key molecular signaling events implicated in antidepressant
responses. Similarly to that observed with pharmacologically diverse
classical antidepressant drugs [8–10], autophosphorylation of TrkB (the
receptor for brain-derived neurotrophic factor or BDNF) and phos-
phorylation of CREBS133 (cAMP response element binding protein) were
readily and rapidly increased in the adult rodent medial prefrontal
cortex upon exposure to anesthetic concentrations of isoflurane [11].
Isoflurane also increased the phosphorylation of p70S6kT412/S424 and
GSK3βS9 (glycogen synthase kinase 3β) [11]. These molecular effects
resemble those induced by rapid-acting antidepressant ketamine
[12,13]. While we also demonstrated that a subanesthetic dose of iso-
flurane (0.3%) showed no such effects [11], the correlation between the
emergence of burst suppression pattern and TrkB and GSK3β phos-
phorylation alterations induced by isoflurane have not yet been in-
vestigated within the same animals. The main purpose of this study was
to test this hypothesis.
2. Material and methods
2.1. Animals
Altogether 18 male C57BL/6JRccHsd mice (8-week-old, 24–26 g,
Harlan Laboratories, Venray, Netherlands) were used in the study.
Animals were maintained under standard laboratory conditions (12-
hour light-dark cycle, temperature 20 ± 1 °C, humidity 60–70%) with
free access to food and water. Mice were housed in groups of four until
surgery and individually thereafter. Nesting and gnawing material was
provided and the cages were enriched with “mouse houses”. Group
sizes were determined on the basis of expected effect size and variation
observed in our three recent publications wherein essentially similar
isoflurane dosing protocol was used [11,14,15]. Food and water
availability, room temperature, humidity and animal wellbeing were
checked daily. Bedding material was changed once per week. After
surgery, bodyweight was measured regularly to monitor weight gain.
Exclusion criteria were poor body condition (no grooming, hunched
posture, reduced/no motor activity) and weight loss> 20%. None of
the animals were excluded from the experiment. All efforts were made
to minimize pain or discomfort of the animals. Experiments were done
in compliance with the European Communities Council Directive of 24
November 1986 (86/609/EEC) and were approved by the County Ad-
ministrative Board of Southern Finland (License nro: ESAVI/10527/
04.10.07/2014).
2.2. Implantation of EEG/EMG electrodes
For the implantation of EEG/EMG-electrodes, all mice were an-
esthetized with isoflurane (3.0% induction, 1.5–2.0% maintenance
(Vetflurane®, Virbac, Switzerland)) and locally with lidocaine (10mg/
ml; Orion Pharma, Finland). Buprenorphine−HCl (0.1 mg/kg, s.c.,;
Indivior, USA) was used for postoperative care. Two epidural screw
EEG electrodes were placed above the fronto-parietal cortex. A further
screw served as mounting support. Two silver wire electrodes were
implanted in the nuchal muscles to monitor the EMG. After surgery,
mice were single-housed in Plexiglas boxes. After a recovery period of
one week, animals were connected to flexible counterbalanced cables
for EEG/EMG recording and habituated to recording cables for 3 days.
2.3. Pharmaco-EEG study and dissection of brain samples
Animals were assigned randomly to treatment groups by drawing
lots: 1% isoflurane anesthesia (n=5), 1.5% isoflurane anesthesia
(n= 5), 2% isoflurane anesthesia (n= 4) and sham (n=4). Mice were
exposed to isoflurane (Vetflurane®, Virbac, Switzerland) in their home
cage for total period of 20min. Airflow was 0.5–0.8 l/min. Sham ani-
mals were kept in their home cages without isoflurane. Animals were
euthanized immediately after the treatments using rapid cervical dis-
location and samples from medial prefrontal cortex collected as pre-
viously described [11,16] by a researcher blinded to experimental
groups. All experiments were performed between 9:00 – 12:00 A.M.
Samples were stored at −80 °C until analysis.
2.4. EEG analysis
The EEG and EMG signals were amplified (gain 5 or 10 K) and fil-
tered (high pass: 1 Hz; low pass 100 Hz) with a 16-channel AC amplifier
(A–M System, model 3500), sampled at 254 Hz or 70 Hz with 1401 unit
(CED), and recorded using Spike2 (version 8.07, Cambridge Electronic
Devices). The EEG data were recorded and processed using Spike2
(version 6, Cambridge Electronic Devices). Bursting activity was de-
tected semi-automatically with the aid of the “Get EEG bursts script”
(kindly provided by Dr. Paul Shepard, University of Maryland School of
Medicine) in Spike2. Burst suppression state was defined as a pattern of
suppressed or absent EEG activity (suppression EEG amplitude ≤ 30%
of baseline) alternated with periods of high amplitude events (burst
EEG amplitude ≥ 130% of baseline).
2.5. Western blot
Western blotting was performed as previously described [11,14,16].
Brain samples were homogenized in a lysis buffer (137mM NaCl,
20mM Tris, 1% NP-40, 10% glycerol, 48mM NaF, H2O, Complete in-
hibitor mix (Roche, Switzerland), PhosphoStop (Roche, Switzerland)),
incubated on ice, centrifuged (16000g, 15min, +4 °C) and the resulting
supernatant collected for further analysis. Sample protein
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concentrations were measured using Bio-Rad DC protein assay (Bio-Rad
Laboratories, Hercules, USA). Samples (40 μg protein) were separated
with SDS-PAGE under reducing conditions and blotted to a PVDF
membrane. Membranes were incubated with the following primary
antibodies (https://scicrunch.org Research Identification Portal Iden-
tity Number (RRID) in brackets): anti-p-GSK3βS9 (#9336,
RRID:AB_331405; 1:000, Cell Signaling Technology (CST)), anti-p-
TrkAY785/TrkBY816 (#4168, RRID:AB_10620952; 1:000, CST), anti-p-
CREBS133 (#9198, RRID:AB_2561044; 1:000, CST), anti-p-p70S6kT412/
S424 (#9234, RRID:AB_2269803, 1:000, CST) and anti-GAPDH (#2118,
RRID:AB_561053; 1:000, CST). Further, the membranes were washed
with TBS/0.1% Tween® (TBST) and incubated with horseradish perox-
idase conjugated secondary antibodies (1:10,000 in non-fat dry milk,
1 h at room temperature; Bio-Rad). After subsequent washes, secondary
antibodies were visualized using enhanced chemiluminescence (ECL
Plus, ThermoScientific, Vantaa, Finland) for detection Bio-Rad Che-
miDoc MP camera (Bio-Rad Laboratories, Helsinki, Finland). The data
were normalized to GAPDH due to our previous observations that si-
milar isoflurane treatment protocol does not affect total protein levels
of investigated molecular targets [11]. The GAPDH levels were also not
affected by isoflurane treatment (data not shown). Processing of the
brain samples and analysis of the western blots were blinded to the
identity of the treatment versus sham groups.
2.6. Statistical analyses
Results are expressed as a percentage of the sham anesthesia and
shown as mean ± SEM (standard error of mean) and normalized to
GAPDH loading control. Two-tailed Mann-Whitney test or one-way
analysis of variance (ANOVA) (two categorical independent variables)
followed by Tukey´s multiple comparison test were used for statistical
evaluation (Prism 7 software, GraphPad (La Jolla, CA, USA). A
P < 0.05 was considered statistically significant. No outlier test was
used to discount any data point and no data were excluded from the
analyses.
3. Results
While the isoflurane dosing regimen utilized in our previous animal
studies is expected to produce burst suppression pattern [14,15], the
correlation between the emergence of burst suppression pattern and
TrkB and GSK3β phosphorylation alterations induced by isoflurane
have not yet been investigated within the same animals. To this end, we
subjected adult male mice pre-implanted with EEG recording electrodes
to varying concentrations of isoflurane for a period of 20min after
which samples from the medial prefrontal cortex were collected for
molecular analyses (Fig. 1A). Isoflurane produced dose-dependent ef-
fect on the phosphorylation of TrkBY816, CREBS133, p70S6kT412/S424 and
GSK3βS9 and most prominent effects were seen with 2% isoflurane, also
used in our previous studies (Fig. 1B) [11–14]. Notably, and as also
seen previously [11], the magnitude of these phosphorylation changes
varied considerably. Phosphorylation of CREBS133 and GSK3βS9 showed
by and large the most prominent changes in response to isoflurane
while phosphorylation of TrkBY816 was less robustly increased com-
pared to sham condition.
We retrospectively divided the animals into two groups based on
their EEG signature while under the influence of isoflurane (burst
suppression / no burst suppression) (Fig. 1C). In all of the animals ex-
posed to highest isoflurane concentration (2.0%), a burst suppression
pattern was readily evident in the EEG, while burst suppression was
Fig. 1. Isoflurane-induced TrkB and GSK3β phosphorylation – potential importance of EEG burst suppression. (A) Schematic representation of the study design. Adult
male mice pre-implanted with recording electrodes were exposed to varying concentrations of isoflurane (1.0%, 1.5% or 2.0%) for a period of 20-minutes under EEG
monitoring after which samples from the medial prefrontal cortex were collected for molecular analyses. Obtained data were correlated to EEG (burst-suppression or
no burst-suppression) within the same animal. (B) Dose-dependent effect of isoflurane on TrkBY816 (F3,15=551), CREBS133 (F3,15=1202), p70S6kT421/424
(F3,15=2423), and GSK3βS9 (F3,15=281) phosphorylation (sham N=4, 1% isoflurane N=5, 1.5% isoflurane N=5, 2% isoflurane N=4). (C) Representative EEG
traces from animals exposed to 2.0%, 1.5% and 1.0% isoflurane. (D) Phosphorylation levels of TrkBY816 (p= 0.3095), CREBS133 (p= 0.0159), p70S6kT421/424
(p=0.0079), and GSK3βS9 (p= 0.0952) in brain samples obtained from mice subjected to 1.0–1.5% isoflurane anesthesia without the emergence of burst sup-
pression pattern (N=6) and sham (N=4). Full statistics are presented in Supplementary Table 1. *p < 0.05; ** p < 0.01; *** p < 0.005, two-tailed Mann-
Whitney test (D) or one-way ANOVA followed by Tukey´s multiple comparison test (E). Abbreviations: BS= burst suppression; CREB= cAMP response element
binding protein; EEG=electroencephalogram; GSK3β = glycogen synthase kinase 3β; Iso= isoflurane; MW=molecular weight; Sham=mice in the induction
chamber for 2min with isoflurane flow; TrkB= tropomyosin related protein kinase B.
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essentially absent in a subgroup of mice subjected to 1.0% or 1.5%
isoflurane (1.0% isoflurane: 4 out of 5; 1.5% isoflurane: 1 out of 5)
(Supplementary Fig. 1A).
To investigate whether the emergence of burst suppression pattern
is prerequisite for the ability of isoflurane to regulate phosphorylation
of TrkBY816, GSK3βS9, CREBS133 and p70S6kT412/S424 we analyzed brain
samples collected from the mice not displaying burst suppression under
isoflurane administration and compared the results to the sham group.
Importantly, phosphorylation of p70S6kT412/S424 and CREBS133 were
increased and GSK3βS9 displayed a trend (p= 0.0952), while phos-
phorylation of TrkBY816 remained unchanged (Fig. 1D). In sum, this
report indicates that isoflurane dose-dependently regulates TrkB and
GSK3β signaling and most prominent changes are seen with a dosing
leading into EEG burst suppression (i.e. deep anesthesia). Burst sup-
pression pattern varied significantly between individual animals, but
the time spent in burst suppression state correlated with the increased
phosphorylation of p70S6kT412/S424 (Supplementary Fig. 1B).
4. Discussion
Activation of BDNF receptor TrkB and inhibition of GSK3β kinase
have been associated with the mechanism of action of rapid-acting
antidepressant ketamine [17,18]. Upon activation TrkB receptors un-
dergo tyrosine phosphorylation within their intracellular domains [19]
and phosphorylation of the autophosphorylation loop (Y705/6) and the
phospholipase-Cγ1 binding site (Y816) are especially regulated by an-
tidepressants [9]. In contrast, phosphorylation of the serine-9 residue
reduces the kinase activity of GSK3β [20]. Our recent study demon-
strates that brief but deep isoflurane anesthesia bring along these mo-
lecular effects [11], providing novel insights into the rapid anti-
depressant effects of isoflurane observed in a subset of depressed
patients [5,6,21]. The rationale to investigate isoflurane in clinical
trials lied upon the idea that post-ictal (i.e. after seizure) emergence of
burst-suppression and/or electrocerebral silence predicts the onset-of-
action of ECT [3–6]. Unlike ECT, isoflurane reliably and reproducibly
produces EEG burst suppression if adequate dosing regimen is used.
Notably, acute electroconvulsive shock (ECS; an animal model of ECT)
has not been shown to activate TrkB [22] although it strongly and ra-
pidly increases BDNF synthesis [23]. Increased TrkB phosphorylation
has been, however, reported after 10-day ECS treatment [24]. Yet, a
single ECS does increase GSK3βS9 phosphorylation gradually after sei-
zure termination [25–27]. This report suggests that isoflurane regulates
p70S6k and GSK3β phosphorylation at a relatively low dose. It is
tempting to speculate that isoflurane might possess antidepressant
properties already at subanesthetic/sedative doses, similarly to that
seen with ketamine [28] and more recently with nitrous oxide (N2O,
laughing gas) [[29]29, see also ref. [16]16]. On the other hand, the
most prominent effects were observed with a dosing leading into EEG
burst suppression, indicating that the depth of anesthesia (and ongoing
metabolic alterations) are somehow coupled with TrkB and GSK3β
signaling. Notably, we recently demonstrated that N2O and flurothyl (a
treatment reminiscent to ECT) regulates TrkB and GSK3β phosphor-
ylation only upon drug withdrawal during a brain state dominated by
slow EEG oscillations that are characteristic for deep sleep [16].
Several drugs, including mood stabilizer lithium (chemical element;
e.g. an inhibitor of inositol monophosphate and GSK3β) [30], classical
antidepressant drugs (e.g. monoamine reuptake blockers) [8,9,31], ni-
modipine (an L-type calcium channel blocker) [32], 7,8-dihydroxy-
flavone (an antioxidant) [33], donepezil (an acetylcholine esterase in-
hibitor) [34], and anesthetics such as ketamine (an N-methyl-D-
aspartate (NMDA) receptor blocker) [10,14] and isoflurane (a GABAA
receptor agonist) [11,14] have been shown to rapidly phosphorylate
TrkB in the adult rodent brain. Among these agents, at least ketamine,
tricyclic antidepressants, lithium and GAs also rapidly increase
GSK3βS9 phosphorylation [11,14,15,27,35]. The pharmacological ac-
tions and effects of these pharmacological compounds are very distinct
implying that several receptor-level mechanisms can drive these see-
mingly similar effects on TrkB and GSK3β signaling. Indeed, while
ketamine is thought to regulate TrkB signaling through BDNF depen-
dent mechanism [10] the precise mechanism underlying the effects of
classical antidepressants and isoflurane remain poorly understood but
seems not to involve BDNF [11,31,36]. Whether these molecular re-
sponses driven through putatively different mechanisms share other
characteristics and functional after effects remain poorly studied. It is
currently unclear whether classical antidepressants and rapid-acting
antidepressants regulate TrkB and GSK3β signaling even in the same
cell populations. High-precision localization studies require, however,
the use of fixed samples for immunohistochemical analysis that must be
prepared using anesthesia during the fixation step. Indeed, this report
adds further evidence on the earlier literature demonstrating that an-
esthesia, that is routinely employed in experimental research involving
laboratory rodents, produce rather profound changes on intracellular
signaling in the brain [14].
A major advance of our experiment set-up was that molecular level
alterations and EEG were analyzed within the same animals. We are
utilizing similar strategy complemented with in-depth time-lapsed EEG
analysis aiming at identifying potential shared EEG signatures corre-
lating with ongoing TrkB and GSK3β signaling alterations induced by
mechanistically distinct treatments carrying rapid antidepressant po-
tential (e.g. subanesthetic ketamine, ECS, isoflurane, N2O) (see Ref.
[16]).
In sum, this brief report demonstrates that isoflurane dose-depen-
dently regulates TrkB and GSK3β phosphorylation in the adult rodent
brain and most prominent changes are observed when burst-suppres-
sion pattern in the EEG emerge.
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